Here, we report a synthetic lethal interaction between targeted PI3Kβ-AKT axis and loss of SETD2 both in vitro (ccRCC-derived cells) and in vivo (ccRCC cell line-derived xenografts). The gene discussed is SETD2; the disease is nonpapillary renal cell carcinoma.